Acarix (OM:ACARIX) - Stock Price, News & Analysis

ACARIX Stock Overview

A medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out.

ACARIX fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 82.95% per year

Risk Analysis

Makes less than USD$1m in revenue (SEK6M)

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap (SEK300M)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

Acarix AB (publ) Competitors

Boule Diagnostics

OM:BOUL

SEK 316.9m

Arcoma

OM:ARCOMA

SEK 197.1m

BrainCool

OM:BRAIN

SEK 529.6m

Neola Medical

OM:NEOLA

SEK 193.6m

Price History & Performance

Summary of all time highs, changes and price drops for Acarix
Historical stock prices
Current Share Price	SEK 0.31
52 Week High	SEK 0.60
52 Week Low	SEK 0.17
Beta	1.43
11 Month Change	-43.49%
3 Month Change	-5.38%
1 Year Change	-30.00%
33 Year Change	-78.28%
5 Year Change	-92.82%
Change since IPO	-98.11%

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Jun 13

Recent updates

Shareholder Returns

	ACARIX	SE Medical Equipment	SE Market
7D	-16.0%	2.6%	1.5%
1Y	-30.0%	15.4%	22.2%

Return vs Industry: ACARIX underperformed the Swedish Medical Equipment industry which returned 15.4% over the past year.

Return vs Market: ACARIX underperformed the Swedish Market which returned 22.2% over the past year.

Price Volatility

Is ACARIX's price volatile compared to industry and market?
ACARIX volatility
ACARIX Average Weekly Movement	11.7%
Medical Equipment Industry Average Movement	6.9%
Market Average Movement	5.7%
10% most volatile stocks in SE Market	12.1%
10% least volatile stocks in SE Market	3.4%

Stable Share Price: ACARIX's share price has been volatile over the past 3 months.

Volatility Over Time: ACARIX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

Founded	Employees	CEO	Website
2009	14	Aamir Mahmood	www.acarix.com

Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States.

Acarix AB (publ) Fundamentals Summary

How do Acarix's earnings and revenue compare to its market cap?
ACARIX fundamental statistics
Market cap	SEK 299.74m
Earnings (TTM)	-SEK 70.95m
Revenue (TTM)	SEK 6.26m

47.9x

P/S Ratio

-4.2x

P/E Ratio

Is ACARIX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACARIX income statement (TTM)
Revenue	SEK 6.26m
Cost of Revenue	SEK 734.00k
Gross Profit	SEK 5.52m
Other Expenses	SEK 76.47m
Earnings	-SEK 70.95m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 07, 2024

Earnings per share (EPS)	-0.073
Gross Margin	88.27%
Net Profit Margin	-1,134.23%
Debt/Equity Ratio	0%

How did ACARIX perform over the long term?

See historical performance and comparison

ACARIX Stock Overview

Rewards

Risk Analysis

Acarix AB (publ) Competitors

OM:BOUL

SEK 316.9m

OM:ARCOMA

SEK 197.1m

OM:BRAIN

SEK 529.6m

OM:NEOLA

SEK 193.6m

Price History & Performance

Recent News & Updates

Second quarter 2024 earnings released: kr0.02 loss per share (vs kr0.051 loss in 2Q 2023)

Acarix Expands Within US Wellness Exam Market

Acarix AB (publ) announced that it expects to receive SEK 21 million in funding

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation Study

Acarix AB (Publ) Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024

Recent updates

Second quarter 2024 earnings released: kr0.02 loss per share (vs kr0.051 loss in 2Q 2023)

Acarix Expands Within US Wellness Exam Market

Acarix AB (publ) announced that it expects to receive SEK 21 million in funding

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation Study

Acarix AB (Publ) Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024

First quarter 2024 earnings released: kr0.019 loss per share (vs kr0.045 loss in 1Q 2023)

Acarix AB (publ) Approves Board Elections

Acarix AB Announces Initiation of the First Us-Based Clinical Workflow Evaluation Study

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: kr0.16 loss per share (vs kr0.31 loss in FY 2022)

Acarix Appoints New Members to the Advisory Board

New major risk - Share price stability

Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million.

Acarix AB (publ) Announces CEO Changes

Chief Operations Officer recently bought kr157k worth of stock

Acarix AB (publ) to Report Q3, 2024 Results on Nov 07, 2024

Acarix AB (publ) Advances the Utilization of Its CADScor System Within the Veterans Administration (Va) Healthcare Network

New major risk - Financial position

Third quarter 2023 earnings released: kr0.038 loss per share (vs kr0.084 loss in 3Q 2022)

Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million.

Price target increased by 18% to kr0.90

Second quarter 2023 earnings released: kr0.051 loss per share (vs kr0.073 loss in 2Q 2022)

Acarix AB (Publ) Appoints Dr. Deepak R. Talreja Md as New Medical Advisor

Acarix AB Elects Mikael Thorén as Director

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021)

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021)

Acarix AB (publ) to Report Fiscal Year 2022 Final Results on Apr 20, 2023

Acarix AB (publ) to Report Q4, 2023 Results on Feb 15, 2024

Acarix AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Acarix AB (publ) to Report Q3, 2022 Results on Nov 16, 2022

Acarix AB (publ) Announces Patient Enrollment Completed in the Filter-Scad Randomized Controlled Multi-Center Trial

Second quarter 2022 earnings released: kr0.073 loss per share (vs kr0.093 loss in 2Q 2021)

Acarix AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

Here's Why We're Watching Acarix's (STO:ACARIX) Cash Burn Situation

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to kr2.60

No independent directors

Acarix AB (publ), Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Acarix Submits Breakthrough Designation Request with Food and Drug Administration for Heart Failure Diagnosis

Acarix AB (Publ) Announces CE Approval and FDA Denovo of CADScor System

Third quarter 2021 earnings released: kr0.076 loss per share (vs kr0.11 loss in 3Q 2020)

We're Keeping An Eye On Acarix's (STO:ACARIX) Cash Burn Rate

Second quarter 2021 earnings released: kr0.093 loss per share (vs kr0.20 loss in 2Q 2020)

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Director has left the company

Director has left the company

Director has left the company

Chairman of the Board Werner Braun has left the company

First quarter 2021 earnings released: kr0.083 loss per share (vs kr0.21 loss in 1Q 2020)

Full year 2020 earnings released: kr0.51 loss per share (vs kr1.83 loss in FY 2019)

Director recently bought kr890k worth of stock

Companies Like Acarix (STO:ACARIX) Are In A Position To Invest In Growth

New 90-day low: kr1.12

Acarix AB (publ) Announces Positive Preliminary Data from the Exploratory SEISMO Study

Acarix Receives US Market Approval for the CADScor System

New 90-day high: kr1.29